The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Investing.com -- Boston Scientific (NYSE:BSX) stock climbed over 1% in premarket trading Wednesday after the company raised its full-year earnings guidance, surpassing the consensus estimate.

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in ...

Boston Scientific BSX has outperformed the market over the past 10 years by 10.35% on an annualized basis producing an average annual return of 22.01%. Currently, Boston Scientific has a market ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

See our leaderboard of companies with the largest price target upside. The projected annual revenue for Boston Scientific is ...

Corporation announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ...